Paclitaxel-Loaded Gelatin Nanoparticles for Intravesical Bladder Cancer Therapy

Ze Lu, Teng‐Kuang Yeh, Max Tsai, +2

Clinical Cancer Research

Effects of Carrier on Disposition and Antitumor Activity of Intraperitoneal Paclitaxel

Max Tsai, Ze Lu, Jie Wang, +3

Pharmaceutical Research

Intraperitoneal PaclitaxelAntitumor ActivityMedicinePharmacologyPharmacotherapy +6

Tumor-Penetrating Microparticles for Intraperitoneal Therapy of Ovarian Cancer

Ze Lu, Max Tsai, Dan Lü, +3

Journal of Pharmacology and Experimental Therapeutics

Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study

Arjan Blokland, Marlies A. van Duinen, Anke Sambeth, +5

Neurobiology of Aging

Acute TreatmentPsychotropic MedicationNeurolinguisticsPhosphodiesterase 4Psychopharmacology +18

Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls

Eric Pearlman, Darren Wilbraham, Ellen B. Dennehy, +4

Human Psychopharmacology Clinical and Experimental

An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients

James Gilleen, Farah Yakub, Cate Davison, +10

Psychopharmacology

Paclitaxel-loaded polymeric microparticles: Quantitative relationships between in vitro drug release rate and in vivo pharmacodynamics

Max Tsai, Ze Lu, M. Guillaume Wientjes, +1

Journal of Controlled Release

NanomedicineEngineeringPolymer-drug ConjugateMedicinePaclitaxel-loaded Polymeric Microparticles +9

Multiscale Tumor Spatiokinetic Model for Intraperitoneal Therapy

Jessie L.‐S. Au, Peng Guo, Yue Gao, +4

The AAPS Journal

MedicineSurgeryBiomedical ModelingIntraperitoneal TherapyOncology +1

A human [ 11 C]T-773 PET study of PDE10A binding after oral administration of TAK-063, a PDE10A inhibitor

Akihiro Takano, Per Stenkrona, Nahid Amini, +8

NeuroImage

Pde10a BindingMedicinePde10a InhibitorImmunologyClinical Pharmacology +4

Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo‐ and Alprazolam‐Controlled Crossover Study

Darren Wilbraham, Paul H. Berg, Max Tsai, +4

The Journal of Clinical Pharmacology